Ribocure Pharmaceuticals AB (Ribocure) is a newly established Swedish biotech company with a business focus on the development of cutting-edge RNA therapeutics. Our mission is to build a world-leading RNA therapeutics R&D company in Sweden and help patients all over the world.
Ribocure’s primary focus lies in addressing the significant medical gaps in rare diseases involved in the fields of cardiovascular, renal, and oncology. The company is dedicated to the discovery and development of groundbreaking drug assets utilizing advanced oligonucleotide technologies. Operating as a subsidiary of Ribo Life Science Co., Ltd., Ribocure leverages the advantages of a vertically integrated oligonucleotide research platform and excels in translational and clinical operations. Our comprehensive technological platforms encompass the entire process, from sequence design, screening, and optimization to delivery technologies and large-scale commercial CMC capacity. In 2022, we successfully progressed three projects to the clinical stage, achieving an impressive average time frame of 20-24 months from concept to implementation.
On the entire fifth floor of the GoCo Clinic building, Ribocure has established a unique “from bench-to-bed” set-up with an R&D department, a Ph2 clinical trial unit, ribocure clinic and an in vitro human cell lab. The Ribocure Clinic is dedicated and specialized for high quality proof of principle/concept and phase 2 trials within our clinical expertise areas including a functional imaging core lab capacity.
Ribocure will be expanding heavily in Sweden and looking for new talents to join, and academic associations as well as small and large enterprise partners to collaborate with, with the joint goal of developing highly differentiated and innovative oligonucleotide therapeutics to help patients in need.
Sitemap
About Ribocure
Contact us
